A recent study found that toxicity is routinely minimized in phase 3 oncology trials, especially those that are not industry sponsored.
And again, it's very important that we educate the population. And when nurses are educated on the different subtypes of breast cancer, then we can also—we feel empowered. And now we can empower the ...
Although participants in the study had greater rates of nonadherence postintervention, those who reported nonadherence at ...
Cilta-Cel Associated With Higher HRQOL for Lenalidomide-Refractory MM ...
Real-World Data Back First-Line Avelumab and Axitinib in Advanced RCC ...
Real-World Data Back First-Line Avelumab and Axitinib in Advanced RCC ...
Cilta-Cel Associated With Higher HRQOL for Lenalidomide-Refractory MM ...
Cilta-Cel Associated With Higher HRQOL for Lenalidomide-Refractory MM ...
The FDA has granted PYX-201 fast track designation for treatment of recurrent or metastatic HNSCC after progression post-chemoimmunotherapy. PYX-201 received FDA fast track designation for use in ...
Real-World Data Back First-Line Avelumab and Axitinib in Advanced RCC ...
Real-World Data Back First-Line Avelumab and Axitinib in Advanced RCC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback